Ricin poisoning

disease
On this page

Summary

Ricin poisoning (MONDO:0035511) is a disease and 3 clinical trials. A subtype of poisoning — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: Unknown (Worldwide) [Orphanet-validated]
  • Clinical trials: 3

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Point prevalence<1 / 1 000 000EuropeValidated

Identifiers

Disease identifiers

FieldValue
Canonical namericin poisoning
Mondo IDMONDO:0035511
Orphanet570470
ICD-10-CMT62.2
GARD0022311
Is cancer (heuristic)no

Disease family

This is a subtype of poisoning. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › poisoningricin poisoning

Related subtypes (58): toxic oil syndrome, infantile mercury poisoning, ketamine-induced biliary dilatation, manganese poisoning, cyanide-induced parkinsonism, colchicine poisoning, methanol poisoning, ethylene glycol poisoning, paraquat poisoning, lead poisoning, mercury poisoning, acute opioid poisoning, acute tricyclic antidepressant poisoning, acute poisoning by drugs with membrane-stabilizing effect, snakebite envenomation, paracetamol poisoning, cyanide poisoning, scorpion envenomation, argyria, acute ackee fruit intoxication, cocaine intoxication, systemic monochloroacetate poisoning, water intoxication, cassavism, formaldehyde poisoning, heavy metal poisoning, abacavir toxicity, allopurinol toxicity, codeine toxicity, efavirenz toxicity, flucloxacilline toxicity, isoniazid toxicity, raltegravir toxicity, voriconazole toxicity, curariform drugs toxicity, statin toxicity, phenytoin or carbamazepine toxicity, letrozole toxicity, ivermectin toxicity, belinostat toxicity or dose selection, toxicity to dolutegravir, mycotoxicosis, ciguatera fish poisoning, lathyrism, cadmium poisoning, phenytoin toxicity, nerve agent poisoning, local anesthetic poisoning, fire ant poisoning, aflatoxicosis, black widow spider envenomation, platinum-induced ototoxicity, carbon monoxide poisoning, organophosphate poisoning, sulfur mustard poisoning, cardiac glycoside intoxication, monochloroacetic acid poisoning, chemotherapy-induced toxicity

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE13

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01846104PHASE1COMPLETEDBooster Dose (50 µg) of Recombinant Ricin Toxin Vaccine (RVEc™) in Previously Vaccinated Healthy Adults
NCT02385825PHASE1WITHDRAWNIM Recombinant Ricin Toxin Vaccine (RVEc) - 3-Dose Primary Series With Boost
NCT02386150PHASE1WITHDRAWNID Recombinant Ricin Toxin A-Chain Vaccine RVEc™ - 3-Dose Primary Series With Boost

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.